A Phase III, Open-label, Randomized, Controlled, Multi-Country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co Administered With PCV20 in Adults Aged 60\xa0Years and Older

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 20-valent conjugate vaccine (Primary) ; Respiratory syncytial virus vaccine adjuvanted (Primary)
Indications Respiratory syncytial virus infections
Focus Pharmacodynamics; Registrational
Sponsors GlaxoSmithKline; GSK

Most Recent Events

02 Jul 2024 Status changed from active, no longer recruiting to completed.
20 Oct 2023 Planned End Date changed from 27 Jun 2024 to 28 May 2024.
20 Oct 2023 Planned primary completion date changed from 15 Jan 2024 to 11 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight